FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1964634806> ?p ?o ?g. }

• W1964634806 endingPage "377" @default.
• W1964634806 startingPage "370" @default.
• W1964634806 abstract "To compare the relative cost-effectiveness ratios of (1) therapy with ondansetron, droperidol, and metoclopramide in the prevention of postoperative nausea and vomiting (PONV), and (2) prophylactic versus rescue therapy of PONV with these agents. Cost-effectiveness analysis based on the estimated costs of 12 mutually exclusive outcomes identified by decision analysis. Computer model of outcome established using data extracted from published studies and a survey of current practice in two university-affiliated hospitals. Patients undergoing operations associated with a high risk of PONV. The cost-effectiveness of prophylactic antiemetic therapy was compared among three drugs and also compared with limiting treatment to established PONV. Direct costs included drug acquisition, drug delivery, equipment used in managing vomiting, and additional nursing time costs. Indirect costs included drugs and materials used to treat persistent nausea and/or vomiting and the side effects of prophylactic drugs, increased time spent in the postanesthesia care unit, unanticipated hospitalization, and lost earnings due to hospitalization. Separate models were created for patients with both nausea and vomiting and with isolated nausea. The total incremental costs associated with the prophylactic use of ondansetron, metoclopramide, and droperidol were $37.74, $28.43, and $18.17 per patient, respectively. The costs per emesis-free patient with the prophylactic use of ondansetron, metoclopramide, and droperidol, were $55.91, $71.08, and $30.15, respectively, and per nausea-free patient $68.93, $82.74, and $33.52, respectively. Prophylactic antiemetic therapy was cost-effective for operations with a high frequency of emesis, whereas treatment of established symptoms was more cost-effective when the frequency was lower. For ondansetron, prophylactic use was cost-effective only when the frequency of emesis exceeded 33%, whereas prophylactic droperidol was cost-effective even if the frequency was 10%. When drug costs, efficacy, and adverse events were all considered, prophylactic droperidol was more cost-effective than ondansetron, and both drugs were more cost-effective than metoclopramide. However, the expected frequency of PONV, as well as local drug acquisition costs, can significantly influence whether a particular antiemetic is cost-effective when given prophylactically or only as therapy for established PONV." @default.
• W1964634806 created "2016-06-24" @default.
• W1964634806 creator A5002240432 @default.
• W1964634806 creator A5072726408 @default.
• W1964634806 date "1994-09-01" @default.
• W1964634806 modified "2023-10-16" @default.
• W1964634806 title "Cost-effectiveness analysis of antiemetic therapy for ambulatory surgery" @default.
• W1964634806 cites W1714144352 @default.
• W1964634806 cites W1970022392 @default.
• W1964634806 cites W1972076840 @default.
• W1964634806 cites W1976532277 @default.
• W1964634806 cites W1982313204 @default.
• W1964634806 cites W1983937675 @default.
• W1964634806 cites W1992475309 @default.
• W1964634806 cites W1997327345 @default.
• W1964634806 cites W1999179893 @default.
• W1964634806 cites W2002983956 @default.
• W1964634806 cites W2009548189 @default.
• W1964634806 cites W2011068459 @default.
• W1964634806 cites W2018351832 @default.
• W1964634806 cites W2021143177 @default.
• W1964634806 cites W2023961725 @default.
• W1964634806 cites W2025392650 @default.
• W1964634806 cites W2041399624 @default.
• W1964634806 cites W2044060999 @default.
• W1964634806 cites W2050034405 @default.
• W1964634806 cites W2052345605 @default.
• W1964634806 cites W2056196971 @default.
• W1964634806 cites W2058522657 @default.
• W1964634806 cites W2074096795 @default.
• W1964634806 cites W2076585267 @default.
• W1964634806 cites W2081609539 @default.
• W1964634806 cites W2090011060 @default.
• W1964634806 cites W2090547058 @default.
• W1964634806 cites W2094291439 @default.
• W1964634806 cites W2109612601 @default.
• W1964634806 cites W2151743950 @default.
• W1964634806 cites W2347783765 @default.
• W1964634806 cites W2396200078 @default.
• W1964634806 cites W3157916008 @default.
• W1964634806 cites W4232521044 @default.
• W1964634806 cites W4238404291 @default.
• W1964634806 cites W4255818521 @default.
• W1964634806 cites W8902029 @default.
• W1964634806 doi "https://doi.org/10.1016/s0952-8180(05)80006-6" @default.
• W1964634806 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7986508" @default.
• W1964634806 hasPublicationYear "1994" @default.
• W1964634806 type Work @default.
• W1964634806 sameAs 1964634806 @default.
• W1964634806 citedByCount "121" @default.
• W1964634806 countsByYear W19646348062012 @default.
• W1964634806 countsByYear W19646348062013 @default.
• W1964634806 countsByYear W19646348062014 @default.
• W1964634806 countsByYear W19646348062015 @default.
• W1964634806 countsByYear W19646348062016 @default.
• W1964634806 countsByYear W19646348062017 @default.
• W1964634806 countsByYear W19646348062019 @default.
• W1964634806 countsByYear W19646348062020 @default.
• W1964634806 crossrefType "journal-article" @default.
• W1964634806 hasAuthorship W1964634806A5002240432 @default.
• W1964634806 hasAuthorship W1964634806A5072726408 @default.
• W1964634806 hasConcept C141071460 @default.
• W1964634806 hasConcept C177713679 @default.
• W1964634806 hasConcept C2777170512 @default.
• W1964634806 hasConcept C2777297131 @default.
• W1964634806 hasConcept C2778479196 @default.
• W1964634806 hasConcept C2779425338 @default.
• W1964634806 hasConcept C2780580376 @default.
• W1964634806 hasConcept C2780852908 @default.
• W1964634806 hasConcept C2780884295 @default.
• W1964634806 hasConcept C35785553 @default.
• W1964634806 hasConcept C42219234 @default.
• W1964634806 hasConcept C71924100 @default.
• W1964634806 hasConceptScore W1964634806C141071460 @default.
• W1964634806 hasConceptScore W1964634806C177713679 @default.
• W1964634806 hasConceptScore W1964634806C2777170512 @default.
• W1964634806 hasConceptScore W1964634806C2777297131 @default.
• W1964634806 hasConceptScore W1964634806C2778479196 @default.
• W1964634806 hasConceptScore W1964634806C2779425338 @default.
• W1964634806 hasConceptScore W1964634806C2780580376 @default.
• W1964634806 hasConceptScore W1964634806C2780852908 @default.
• W1964634806 hasConceptScore W1964634806C2780884295 @default.
• W1964634806 hasConceptScore W1964634806C35785553 @default.
• W1964634806 hasConceptScore W1964634806C42219234 @default.
• W1964634806 hasConceptScore W1964634806C71924100 @default.
• W1964634806 hasIssue "5" @default.
• W1964634806 hasLocation W19646348061 @default.
• W1964634806 hasLocation W19646348062 @default.
• W1964634806 hasOpenAccess W1964634806 @default.
• W1964634806 hasPrimaryLocation W19646348061 @default.
• W1964634806 hasRelatedWork W1647152998 @default.
• W1964634806 hasRelatedWork W2005836419 @default.
• W1964634806 hasRelatedWork W2006229556 @default.
• W1964634806 hasRelatedWork W2037730757 @default.
• W1964634806 hasRelatedWork W2058522657 @default.
• W1964634806 hasRelatedWork W2147223907 @default.
• W1964634806 hasRelatedWork W2166413311 @default.
• W1964634806 hasRelatedWork W2393107062 @default.

• next